DK1287142T3 - Nukleinsyremolekyle omfattende en for et SDF-1 gamma chemokin, en neuropeptid-præcursor eller mindst et neuropeptid kodende nukleinsyresekvens - Google Patents
Nukleinsyremolekyle omfattende en for et SDF-1 gamma chemokin, en neuropeptid-præcursor eller mindst et neuropeptid kodende nukleinsyresekvensInfo
- Publication number
- DK1287142T3 DK1287142T3 DK01936423T DK01936423T DK1287142T3 DK 1287142 T3 DK1287142 T3 DK 1287142T3 DK 01936423 T DK01936423 T DK 01936423T DK 01936423 T DK01936423 T DK 01936423T DK 1287142 T3 DK1287142 T3 DK 1287142T3
- Authority
- DK
- Denmark
- Prior art keywords
- neuropeptide
- nucleic acid
- sdf
- acid molecule
- acid sequence
- Prior art date
Links
- 102000003797 Neuropeptides Human genes 0.000 title abstract 7
- 108090000189 Neuropeptides Proteins 0.000 title abstract 7
- 150000007523 nucleic acids Chemical class 0.000 title abstract 5
- 102000019034 Chemokines Human genes 0.000 title abstract 3
- 108010012236 Chemokines Proteins 0.000 title abstract 3
- 108020004707 nucleic acids Proteins 0.000 title abstract 3
- 102000039446 nucleic acids Human genes 0.000 title abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 title abstract 2
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 title abstract 2
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 title abstract 2
- 239000002243 precursor Substances 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 abstract 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 abstract 1
- 238000003149 assay kit Methods 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10027383A DE10027383A1 (de) | 2000-06-02 | 2000-06-02 | Nukleinsäure-Molekül umfassend eine für ein Chemokin, einen Neuropeptid-Präkursor oder mindestens ein Neuropeptid kodierende Nukleinsäuresequenz |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1287142T3 true DK1287142T3 (da) | 2006-03-13 |
Family
ID=7644466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01936423T DK1287142T3 (da) | 2000-06-02 | 2001-06-01 | Nukleinsyremolekyle omfattende en for et SDF-1 gamma chemokin, en neuropeptid-præcursor eller mindst et neuropeptid kodende nukleinsyresekvens |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20030215792A1 (enExample) |
| EP (1) | EP1287142B1 (enExample) |
| JP (1) | JP2004521607A (enExample) |
| AT (1) | ATE309361T1 (enExample) |
| AU (1) | AU6233501A (enExample) |
| DE (2) | DE10027383A1 (enExample) |
| DK (1) | DK1287142T3 (enExample) |
| ES (1) | ES2251483T3 (enExample) |
| WO (1) | WO2001092530A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004232972A1 (en) * | 2003-04-16 | 2004-11-04 | Argyll Biotechnologies, Llc | Prophylactic and therapeutic benefits of new class of immune stimulating peptides |
| WO2006124013A2 (en) * | 2004-04-30 | 2006-11-23 | Five Prime Therapeutics, Inc. | Novel stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof, and method of use |
| UA96926C2 (ru) * | 2005-10-31 | 2011-12-26 | Мерк Сероно Са | Применение sdf-1 для лечения и/или профилактики неврологических заболеваний |
| AU2007237840A1 (en) * | 2006-04-07 | 2007-10-25 | Neuro Therapeutics Ab | Survival and development of neural cells |
| WO2008003780A2 (en) * | 2006-07-07 | 2008-01-10 | TRÖSCHER, Herbert | Use of proteins of the sdf-1-family for improvement of axonal plasticity or for axonal regeneration following lesions |
| US7696309B2 (en) | 2006-10-23 | 2010-04-13 | The Brigham And Women's Hospital, Inc. | Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage |
| EP2197907A2 (en) * | 2007-10-15 | 2010-06-23 | Centre National De La Recherche Scientifique-CNRS | Cxcl12 gamma a chemokine and uses thereof |
| US9308277B2 (en) | 2010-02-25 | 2016-04-12 | Mesoblast International Sàrl | Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage |
| US10662234B2 (en) | 2011-06-07 | 2020-05-26 | Mesoblast International Sàrl | Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| US5885794A (en) * | 1991-05-10 | 1999-03-23 | The Salk Institute For Biological Studies | Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily |
| CA2117953C (en) * | 1993-10-14 | 2001-12-11 | Tasuku Honjo | Human stromal derived factor 1 alpha and 1 beta and dnas encoding the same |
| US6114502A (en) * | 1996-04-10 | 2000-09-05 | Axys Pharmaceuticals, Inc. | Gene family associated with neurosensory defects |
| EP0892807A1 (en) * | 1996-04-10 | 1999-01-27 | Axys Pharmaceuticals, Inc. | Gene family associated with neurosensory defects |
| US6100387A (en) * | 1997-02-28 | 2000-08-08 | Genetics Institute, Inc. | Chimeric polypeptides containing chemokine domains |
| MXPA00003885A (es) * | 1997-10-22 | 2004-04-23 | Inst Genetics Llc | Quimiocinas con modificiaciones de la terminacion amino. |
| US6747137B1 (en) * | 1998-02-13 | 2004-06-08 | Genome Therapeutics Corporation | Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics |
| WO1999055915A2 (en) * | 1998-04-29 | 1999-11-04 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | IDENTIFICATION OF POLYMORPHISMS IN THE PCTG4 REGION OF Xq13 |
| AU5134799A (en) * | 1998-07-30 | 2000-02-21 | Human Genome Sciences, Inc. | 98 human secreted proteins |
| AU2201801A (en) * | 1999-12-16 | 2001-06-25 | Ribotargets Limited | Assays |
-
2000
- 2000-06-02 DE DE10027383A patent/DE10027383A1/de not_active Ceased
-
2001
- 2001-06-01 JP JP2002500722A patent/JP2004521607A/ja active Pending
- 2001-06-01 ES ES01936423T patent/ES2251483T3/es not_active Expired - Lifetime
- 2001-06-01 DE DE50108009T patent/DE50108009D1/de not_active Expired - Lifetime
- 2001-06-01 AT AT01936423T patent/ATE309361T1/de not_active IP Right Cessation
- 2001-06-01 EP EP01936423A patent/EP1287142B1/de not_active Expired - Lifetime
- 2001-06-01 DK DK01936423T patent/DK1287142T3/da active
- 2001-06-01 WO PCT/EP2001/006250 patent/WO2001092530A1/de not_active Ceased
- 2001-06-01 AU AU62335/01A patent/AU6233501A/en not_active Abandoned
-
2002
- 2002-12-02 US US10/308,322 patent/US20030215792A1/en not_active Abandoned
-
2008
- 2008-01-22 US US12/010,221 patent/US20080319165A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1287142A1 (de) | 2003-03-05 |
| JP2004521607A (ja) | 2004-07-22 |
| WO2001092530A1 (de) | 2001-12-06 |
| AU6233501A (en) | 2001-12-11 |
| EP1287142B1 (de) | 2005-11-09 |
| US20030215792A1 (en) | 2003-11-20 |
| US20080319165A1 (en) | 2008-12-25 |
| DE50108009D1 (de) | 2005-12-15 |
| ATE309361T1 (de) | 2005-11-15 |
| ES2251483T3 (es) | 2006-05-01 |
| DE10027383A1 (de) | 2001-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0500345A2 (hu) | Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására | |
| EA200001023A1 (ru) | Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью | |
| BRPI0315666B8 (pt) | dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos | |
| ATE354638T1 (de) | Menschlicher gewebsinhibitor von metalloproteinase-4 | |
| AR047729A1 (es) | Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe) | |
| HUP0203409A2 (hu) | Gamma-interferon-konjugátumok | |
| AR020048A1 (es) | Un polipeptido dependiente de la vitamina k, una composicion farmaceutica que lo comprende, el uso del mismo para la manufactura de un medicamento, unacido nucleico aislado que codifica a dicho polipeptido y una celula hospedante de mamifero. | |
| Yang et al. | Comparative analysis of whole saliva proteomes for the screening of biomarkers for oral lichen planus | |
| DK1287142T3 (da) | Nukleinsyremolekyle omfattende en for et SDF-1 gamma chemokin, en neuropeptid-præcursor eller mindst et neuropeptid kodende nukleinsyresekvens | |
| ATE70280T1 (de) | Charakteristische polypeptide und antikoerper vom papillomavirus, diagnostische verfahren und dieselben verwendende impfungen. | |
| HUP9903921A2 (hu) | Tumor nekrózis faktorral rokon ligandum | |
| DE602005026931D1 (de) | Verwendung von vorstufen von enkephalinen und/oder deren fragmenten in der medizinischen diagnostik | |
| ATE278780T1 (de) | Humanes chemokin beta-13 | |
| MY141459A (en) | Recombinant anti-idiotypic antibodies | |
| DK0932689T3 (da) | Assay for homocystein og homocysteindesulphurase fra protozo-trichomonas vaginalis | |
| TR200103339T2 (tr) | Geliştirilmiş çözülürlük özelliklerine sahip yeni LHRH-antagonistleri. | |
| DE68922297D1 (de) | Für das menschliche angiotension-umformungsenzym (ace) kodierende nukleinsäure und ihre anwendungen, insbesondere zur in-vitro-diagnose von bluthochdruck. | |
| DE60125537D1 (de) | Zusammensetzung zur diagnose und behandlung von herpes simplex virusinfektionen | |
| DE60118359D1 (de) | Humanische pellino-polypeptide | |
| BRPI0407031A (pt) | Composições e métodos para tratamento de câncer empregando igsf9 e liv-1 | |
| ES2151557T3 (es) | Corpusculos de proteinas de estaño, estanniocalcina. | |
| AP2000001917A0 (en) | Gene encoding labyrinthin, a marker for cancer. | |
| Michiels et al. | Carcinoma cell‐derived chemokines and their presence in oral fluid | |
| AR019864A1 (es) | Proceso para producir el antigeno de toxoplasma sag1 o fragmentos del mismo; proteina sag1 o fragmentos de la misma expresada en dicho proceso;composiciones de vacuna que comprendan dicha proteina sag1 o fragmentos de la misma; uso de dicha proteina para la manufactura de medicamentos para preveniry | |
| NO993653D0 (no) | Fremgangsmåte for diagnose, prognose og behandling av glaukom og relaterte sykdommer |